This is a routine tax-withholding sale tied to equity vesting, not a discretionary insider sale. No signal of changing insider sentiment. Monitor future Form 4 filings for any discretionary sales by officers.
RCKT drugs
RCKT drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $2.53entry
- T+1 · 7d ago −3.16%α −2.79% · $2.45
- T+5 · 20h ago −14.62%α −12.93% · $2.16
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Christopher James Stevens, an officer of Rocket Pharmaceuticals, filed a Form 144 notice to sell 16,131 shares of common stock valued at approximately $37,530. The shares were acquired via restricted stock vesting on November 4, 2026, and the sale is intended to cover a tax obligation from the settlement of a vested equity award. This is a routine insider sale for tax withholding purposes, not a discretionary portfolio liquidation.
Key Facts
- Reporting person: Christopher James Stevens, an officer of Rocket Pharmaceuticals
- Shares to be sold: 16,131 shares of common stock
- Estimated value: $37,530.38
- Shares acquired on November 4, 2026 via restricted stock vesting from the issuer
- Sale purpose: cover tax obligation from vested equity award distribution
- Broker: Fidelity Brokerage Services LLC
- Filing date: November 9, 2026
- Market cap of issuer: $267M
Financial Impact
Sale of 16,131 shares valued at ~$37,530, representing about 0.014% of market cap
Risk Factors
- Form 144 is an intent to sell; the actual sale may not occur
- No other insider trading context provided to assess pattern
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-007868 |
| Document: 0001959173-26-007868-index.html | 0001959173-26-007868 |
| Document: 0001959173-26-007868.txt | 0001959173-26-007868 |
Track record
21 reports on RCKT
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Viewing Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers